// App-Quantinova.ai

e20559 : Preliminary results of a phase Ib trial of savolitinib combined with gefitinib in EGFR-mutant lung cancer.

Researchers

Presenter

  • Jin-Ji Yang

Principal Investigators

  • Liu Yang

  • Andrew Farnsworth

  • Amir Handzel

  • Tanya Coleman

  • Shethah Morgan

  • Yi-Long Wu

Medical Centers

  • Guangdong Lung Cancer Inst, Guangzhou, China

  • AstraZeneca, Shanghai, China

  • AstraZeneca, Macclesfield, United Kingdom

  • AstraZeneca, Boston, MA

  • Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China

Locations

  • United States

  • China

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Non Small Cell Lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • Savolitinib

  • gefitinib

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02374645

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved